Mayo Clinic Laboratories, a reference lab at the Rochester, Minn.-based health system, is partnering with genomics company Helix to assist the biopharma industry with drug discovery.
"This collaboration will allow biopharma companies to access molecular and nonmolecular testing services needed across the drug development process," said William Morice II, MD, PhD, president and CEO of Mayo Clinic Laboratories, in a joint Jan. 10 news release. "In addition to the testing knowledge, our Mayo Clinic physicians and scientists are available for consultation during this process to provide their expertise and guidance."
The partnership will give biopharma customers lab testing support and access to Helix's genetic sequencing capabilities and Mayo's more than 3,800 tests and pathology services. Mayo has previously worked with Helix to create a genomics database.